Moderna's Roller Coaster: What $1,000 at Every Stage Would Be Worth

No stock tells the story of the 2020s better than Moderna. A $20 billion biotech that became a $200 billion pandemic hero, then crashed 90% from its peak, and is now staging a comeback with a pipeline beyond COVID vaccines. The "what if" depends entirely on when you got in.

Three entry points, three very different outcomes

The pre-COVID bet (2018)

$1,000 in Moderna in 2018 is worth about $3,365 today. That's a +237% return. Not bad, but it hides a wild ride. That $1,000 briefly hit over $25,000 at Moderna's August 2021 peak of $484 per share. Then it crashed. If you held through the entire roller coaster, you're still up - but you gave back 85% of your peak gains.

The pandemic entry (2020)

$1,000 in early 2020 is worth $2,505. You caught Moderna right before the pandemic made mRNA a household term. COVID vaccines generated $36 billion in revenue over two years. But the stock peaked in August 2021 and has been declining since as vaccine demand fell.

The late entry (2023)

$1,000 in 2023 is worth just $292. That's a -71% loss. You bought after the initial crash but before the stock fell further as COVID booster uptake disappointed and Moderna's cancer vaccine pipeline was still years from revenue.

The 2026 comeback

Moderna is up over 80% year-to-date in 2026. The RSV vaccine launched, the flu-COVID combo vaccine is in late trials, and the cancer vaccine partnership with Merck is showing promising data. The mRNA platform that made COVID vaccines is now being applied to oncology, rare diseases, and autoimmune conditions.

Whether this rebound lasts depends on pipeline execution, not pandemic demand. Moderna's story is a reminder that timing matters enormously - and that the "right" stock at the "wrong" time can still lose you money.

See how Moderna compares to other healthcare stocks like Eli Lilly and Intuitive Surgical, or read about other worst-case timing scenarios.